Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1722 dose-finding study in hyperphosphatemia in hemodialysis patients with end-stage renal disease
2013-004319-33Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tenapanor in hyperphosphatemia (5 arms), sponsored by AstraZeneca. Primary endpoint: Change in serum phosphate levels. Started Jan 2014; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on 2013-004319-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004319-33.